This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Huhn D et al. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98: 1326–1331
O'Brien S et al. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19: 2165–2170
Di Gaetano N et al. (2001) Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114: 800–809
Schulz H et al. (2002) Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100: 3115–3120
Byrd JC et al. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101: 6–14
Keating MJ et al. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol [10.1200/JCO.2005.12.051]
Acknowledgements
The synopsis was written by Emma Campbell, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Hallek has received research support from Schering AG, Roche and Amgen.
Glossary
- OVERALL SURVIVAL
-
Measured from date of randomization to date of death or last contact
- PROGRESSION-FREE SURVIVAL
-
Time from randomization to progression, death or last follow-up
- COMPLETE RESPONSE
-
Maintained for 2 months, as defined by the 1996 National Cancer Institute-sponsored Working Group Guidelines
Rights and permissions
About this article
Cite this article
Hallek, M. Chemoimmunotherapy—towards real progress in the treatment of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2, 338–339 (2005). https://doi.org/10.1038/ncponc0202
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0202